Surrozen (NASDAQ:SRZN – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Profitability
This table compares Surrozen and Tectonic Therapeutic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | N/A | -120.51% | -54.68% |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
Risk & Volatility
Surrozen has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 0 | 0 | 1 | 0 | 3.00 |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
Surrozen currently has a consensus target price of $45.00, suggesting a potential upside of 298.23%. Tectonic Therapeutic has a consensus target price of $72.25, suggesting a potential upside of 54.58%. Given Surrozen’s higher possible upside, equities analysts plainly believe Surrozen is more favorable than Tectonic Therapeutic.
Insider and Institutional Ownership
66.6% of Surrozen shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 43.5% of Surrozen shares are held by company insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Surrozen and Tectonic Therapeutic”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $12.50 million | 2.94 | -$43.04 million | N/A | N/A |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -7.94 |
Tectonic Therapeutic has lower revenue, but higher earnings than Surrozen.
Summary
Tectonic Therapeutic beats Surrozen on 7 of the 11 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
